VHPRG-HDRPH: Effect of Opioids in Neuropathic Pain in Postherpetic Patients

Sponsor
Medical University of Vienna (Other)
Overall Status
Unknown status
CT.gov ID
NCT01102101
Collaborator
WWTF, Wiener Wissenschafts-, Forschungs- und Technologiefonds (Other), Vienna General Hospital (Other)
30
2
7
15
2.2

Study Details

Study Description

Brief Summary

Postherpetic neuralgia (PHN) is often associated with pain and sensory changes and is the leading type of neuropathic pain in modern clinical pain research. It is characterized by a variety of sensory patterns, which may be categorized into "irritable nociceptor" and "impairment of nociceptor". At date, several lines of evidence lead to the assumption, that mechanical hyperalgesia in PHN is based - at least in part - on central nervous processes of sensitization.

In animal studies the investigators have discovered a previously unrecognized effect of opioids, the reversal of long-term potentiation (LTP) at C-fibre synapses, i.e. an opioid-induced depotentiation. In principle, synaptic depotentiation may be permanent or transient. In our study the clinically used ultra-short acting MOR agonist remifentanil normalized synaptic strength after wash-out of the drug. At present it is not known whether opioid-induced depotentiation can be used to the benefit of pain patients.

The aim is to study the hypothesis, that pain in a group of PHN patients with predominant mechanical hyperalgesia is reversed by intravenous remifentanil at a plasma target concentration of 18ng/ml (corresponding to about 0.75 µg/kg/min) for 60 minutes compared with PHN patients of other sensory types.

Condition or Disease Intervention/Treatment Phase
Phase 3

Study Design

Study Type:
Interventional
Anticipated Enrollment :
30 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Basic Science
Official Title:
Effect of Opioids in Neuropathic Pain in Postherpetic Patients
Study Start Date :
Aug 1, 2010
Anticipated Primary Completion Date :
Mar 1, 2011
Anticipated Study Completion Date :
Mar 1, 2011

Outcome Measures

Primary Outcome Measures

  1. Stimulus-response (SR)-function [7 days]

Secondary Outcome Measures

  1. Pinprick [7 days]

    Area of secondary hyperalgesia assessed by pinprick

  2. Area of dynamic allodynia [7 days]

    Brush, Q Tip, Cotton Wool

  3. NRS [7 days]

    Pain according to numeric rating scale (NRS)

  4. Mechanical pain threshold [7 days]

    Mechanical pain threshold measured with v. Frey Filaments

  5. HPPT [7 days]

    Heat pain perception threshold (HPPT) with thermal sensory analyzer (TSA)

  6. HPTT [7 days]

    Heat pain tolerance threshold (HPTT) measured with TSA

  7. Coolness [7 days]

    Coolness perception threshold measured with TSA

  8. Warmth [7 days]

    Warmth perception threshold measured with TSA

  9. LDPI [7 days]

    Laser Doppler Perfusion Imager (LDPI) measuring superficial perfusion of the dermatome

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients suffering from PHN.

  • Pain ≥ 4 out of 10 in numeric rating scale (NRS)

  • Female and male patients above the age of 18

  • Ability to understand/write/read german

Exclusion Criteria:
  • Zoster affecting trigeminal-, opticus region

  • Any somatic pain which is stronger than the neuropathic pain

  • Severe progressive disease

  • Acute cardiac decompensation

  • Known cardiac valve dysfunction

  • Known pulmonary hypertension

  • Cardiac conduction disturbance

  • Active herpetic lesion

  • Opioid therapy

  • Asthma bronchial

  • Chronic obstructive pulmonary disease >GOLD II

  • Severe psychiatric condition

  • Abuse of alcoholic beverages, drug abuse

  • Negative neuropathic symptoms

  • Pregnancy or breast feeding

  • Participation in a clinical trial in the 2 weeks preceding the study

  • Allergy against any medication used in the study protocol

Contacts and Locations

Locations

Site City State Country Postal Code
1 General Hospital Vienna, Medical University of Vienna Vienna Austria 1090
2 Wilhelminenspital der Stadt WIen Vienna Austria 1160

Sponsors and Collaborators

  • Medical University of Vienna
  • WWTF, Wiener Wissenschafts-, Forschungs- und Technologiefonds
  • Vienna General Hospital

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
, ,
ClinicalTrials.gov Identifier:
NCT01102101
Other Study ID Numbers:
  • VHPRG-HighDoseRemiPostHerpetic
First Posted:
Apr 12, 2010
Last Update Posted:
Apr 12, 2010
Last Verified:
Apr 1, 2010
Keywords provided by , ,
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 12, 2010